Chapter 34: Substance Use Disorders III: Nicotine and Smoking

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine a substance that hits the brain so fast, I mean 10 seconds flat, that it physically rewires your neural pathways before you've even fully exhaled.

Right, it's wild.

Usually when we look at standard clinical presentations,

we like to separate the strictly structural from the purely behavioral.

Like a broken femur is structural, right?

You set the bone.

A bad habit is behavioral, so you counsel the patient.

Yeah, exactly.

But then you encounter a chemical that completely obliterates that line.

You aren't just looking at a bad habit anymore, you're looking at a completely hijacked central nervous system.

And that forces clinicians to completely shift their mindset.

You need a highly specific evidence -based pharmacological toolkit because the underlying path physiology of that hijacked system is actively working against your therapeutic goals.

Which is exactly why we're diving into this today.

So for you, the advanced practice nursing or physician assistant student listening right now, consider us your personal study buddies.

We're so glad you're here.

We're doing a comprehensive textbook to practice breakdown of Chapter 34 from Lennie's Pharmacotherapeutics, which covers the pharmacology of nicotine and smoking cessation.

Our mission for this deep dive is to help you connect the dots from the underlying path of physiology directly to rational drug selection.

Okay, let's unpack this.

Let's do it.

And I think the best place to start is the physical journey of the drug itself.

Like how does a chemical even manage to take over the system so efficiently?

Well, it really all comes down to pharmacokinetics, which dictate its massive addictive potential.

First we have to look at absorption.

Nicotine's absorption is entirely dependent on the delivery system.

When a patient inhales cigarette smoke, the nicotine is absorbed primarily in the lungs and the efficiency is just staggering because the massive surface area of the alveoli is so richly supplied with blood, between 90 % and 98 % of the nicotine that enters the lungs crosses directly into the bloodstream.

Wow.

And the text actually makes a really clear distinction here between cigarettes and things like cigars or smokeless tobacco.

The absorption pathways are completely different.

They are, yeah.

Because cigarette smoke is slightly acidic, meaning the nicotine isn't absorbed very well through the mucous membranes of the mouth, so the user is forced to inhale it deep into the lungs to get the effect.

Oh, interesting.

But conversely, the nicotine in cigar smoke and smokeless tobacco is more alkaline, so it's absorbed primarily and quite easily right through the lining of the mouth.

Got it.

But regardless of the entry point, nicotine is highly lipid soluble.

It crosses cellular membranes easily and distributes widely throughout the entire body.

And the speed of that distribution is terrifying.

When inhaled in cigarette smoke, nicotine reaches the brain in just 10 seconds.

Yeah, 10 seconds.

That is essentially the equivalent of an intravenous drug push.

Like, if I give a patient an IV medication, I expect an immediate physiological response.

Is that 10 -second transit time the reason why cigarettes are so much more behaviorally addictive than, say, a nicotine patch?

Absolutely.

What's fascinating here is the speed of delivery is the primary driver of the brain's reward conditioning.

That 10 -second spike provides an immediate, massive chemical re -enfraacement.

Your brain instantly links the physical action, right?

Like raising the cigarette, inhaling, exhaling, to an immediate neurochemical reward.

Exactly.

You are training the brain in real time.

Now, once it's in the system, it's rapidly metabolized in the liver to inactive products and excreted by the kidneys.

Its half -life is remarkably short, just one to two hours.

Which perfectly explains that constant urge to light up again.

I mean, the reward fades almost as fast as it arrives, leaving the patient in this perpetual state of chemical withdrawal.

Yeah, it's a vicious cycle.

We have this constant cycle of spiking and crashing, and that directly leads into the chaos it causes throughout the body.

The text outlines the pharmacologic effects of the low -dose nicotine you get from smoking,

and it touches nearly every organ system.

Let's break down exactly how it does that, starting with the cardiovascular system.

Nicotine activates nicotinic receptors in the sympathetic ganglia and the adrenal medulla.

This promotes the release of norepinephrine from sympathetic nerves and epinephrine directly from the adrenals.

And clinically, we know exactly what norepinephrine and epinephrine do.

Norepinephrine hits the alpha -1 receptors in the vasculature, which causes systemic vasoconstriction, and then epinephrine hits the beta -1 receptors in the heart, causing tachycardia and increased contractility.

So the heart is pumping faster and harder against much tighter pipes.

Precisely.

And the net result of that is significantly elevated blood pressure and an immense increase in cardiac work.

And those specific physiological effects are the primary underlying cause of cardiovascular deaths in chronic smokers.

But then we also have to look at the gastrointestinal system.

By the GI tract.

Here, nicotine activates nicotinic receptors in the parasympathetic ganglia.

This drastically increases the secretion of gastric acid and augments the tone and motility of GI -smooth muscle.

It also triggers a highly complex vomiting reflex involving chemoreceptors in the aortic arch, the carotid sinus, and the central nervous system.

Wait, I have to pause here because this is a massive physiological paradox.

It hits the sympathetic nervous system to rev up the heart and constrict the blood vessels, but it simultaneously hits the parasympathetic system to churn up the stomach acid and increase GI motility.

That's exactly what it does.

It's literally stepping on the gas and the brakes at the exact same time.

It is a total autonomic tug of war.

The body is not designed to have the sympathetic fight or flight system and the parasympathetic rest and digest system fully activated simultaneously.

Obviously not.

So this systemic chaos, this constant state of being chemically pulled in opposing directions, is exactly why chronic smoking injures nearly every single organ in the body.

And the central nervous system is definitely not spared.

Nicotine is a potent CNS stimulant.

It stimulates respiration.

It physically alters brainwaves to produce an arousal pattern on an EEG, and it has multiple psychological effects.

Yeah, quite a few.

It increases alertness, facilitates memory, improves cognition, reduces aggression, and famously suppresses appetite.

But the clincher is what it does to dopamine.

By promoting the release of dopamine, it heavily activates the brain's pleasure system in the mesolimbic area.

And for your clinical context, you must understand that the effects of nicotine on this mesolimbic pleasure system are identical to the effects of other highly addictive, heavily regulated drugs.

Like which ones?

Specifically cocaine, amphetamines, and opioids.

It is hitting the exact same biochemical pathways.

Which really reframes the devastating statistics outlined in the text.

When you realize the entire American healthcare system is battling a biochemical loop identical to cocaine addiction, the numbers make a lot more sense.

They really do.

Cigarette smoking remains the greatest single cause of preventable illness and premature death.

In the U .S., it kills over 480 ,000 adults each year.

That is one out of every five deaths.

It's staggering.

Globally, it's over 8 million people annually.

Males lose an average of 13 .2 years of life, females lose 14 .5 years, and direct medical costs are over $170 billion.

The sheer scale of destruction stemming from a simple receptor -level dopamine loop is hard to fully comprehend.

And while tobacco smoke contains dangerous compounds like carbon monoxide, hydrogen cyanide, nitrosamines, and carcinogenic tar.

Yeah, the really bad stuff.

Right.

But nicotine is the driver that keeps patients inhaling those poisons.

This is why the FDA, under the Family Smoking Prevention and Tobacco Control Act, has the authority to restrict marketing to youth, require prominent warning labels,

mandate the disclosure of ingredients, and critically mandate the gradual reduction of nicotine to non -addictive levels in tobacco products.

So we know it's hijacking the mesolimic pathway, but how exactly is this drug operating at the receptor level?

The text discusses mechanism of action, and it notes that nicotine is highly dose dependent.

The dose dependency is fascinating.

Low doses, like the amounts a patient receives from smoking a single cigarette, activate nicotinic receptors, but high doses actually block those same receptors.

Because smoking provides relatively low doses, it causes consistent receptor activation, primarily in the autonomic ganglia, the adrenal medulla, the carotid body, the aortic arch, and the CNS.

So how does this apply to special populations, specifically pregnancy and lactation?

Because obviously we want to eliminate all nicotine exposure.

Absolutely.

Nicotine exposure during gestation harms the fetus, and nicotine in breast milk harms the nursing infant.

However, the clinical guideline here requires a pragmatic risk assessment.

Meaning?

Well, because pharmaceutical nicotine, like patches or gum, is definitively safer than inhaling tobacco smoke.

I mean, smoke contains high levels of carbon monoxide that starves the fetus of oxygen, along with thousands of other toxins.

So it is clinically reasonable to consider using nicotine replacement therapy during pregnancy to help a patient quit smoking.

That's a really vital clinical distinction.

You are trading a highly dangerous toxic delivery mechanism for a much safer, controlled one to protect the fetal environment.

Let's talk about the reality of chronic use, specifically tolerance and dependence.

The text notes that tolerance develops to some effects, but not all of them.

Like a novice smoker will experience intense nausea and dizziness, but they quickly build tolerance to that.

To the nausea, yes.

But crucially, very little tolerance develops to the cardiovascular effects.

Long -term smokers continue to experience increased blood pressure and increased cardiac work every single time they light up.

So the GI system, the brain, get used to the dizziness, kind of like getting your sea legs on a boat.

But the cardiovascular system never gets a break.

The heart never gets sea legs.

If we connect this to the bigger picture, that relentless overwork year after year is exactly why chronic smoking leads directly to ischemic heart disease.

It makes perfect sense.

The heart is in a constant state of oxygen demand, while the carbon monoxide in the smoke simultaneously reduces oxygen supply.

And this lack of tolerance is why quitting at any age provides almost immediate cardiovascular benefits.

But quitting triggers profound dependence and withdrawal.

The withdrawal syndrome is severe.

We're talking intense craving, nervousness, restlessness, irritability, hostility, insomnia,

impaired concentration, and significant weight gain.

It's awful for the patient.

It starts within 24 hours of the last cigarette, and can last for weeks to months.

The text actually notes that women generally report more discomfort than men during withdrawal.

Interestingly,

experience has shown that abrupt discontinuation, so just quitting cold turkey, may actually be more effective for some patients than gradual reduction.

We clearly see the chronic toll over decades.

But we also need to address the other extreme.

The margin of safety for an acute dose is shockingly narrow.

Here's where it gets really interesting.

This blew my mind when reviewing the text.

Acute poisoning from nicotine is highly toxic.

Doses as low as 40 mg can be fatal.

Just 40 mg?

Clinically, you'll see this mostly in pediatric exposures, right?

Like children who ingest discarded tobacco products, or people exposed to nicotine -containing insecticides.

Unfortunately, yes.

The symptoms of acute poisoning are severe and involve total systemic overload.

You'll see extreme nausea, severe salivation, vomiting, diarrhea, cold sweats, confusion, faintness, and a pulse that is rapid, weak, and irregular.

That sounds terrifying.

Ultimately, death results from respiratory paralysis, both from the drug's direct effects on the muscles of respiration and its inhibitory effects on the central nervous system.

So if a toddler gets into a nicotine insecticide and receives a lethal 40 mg dose, how do we even reverse that?

Is there a specific receptor antagonist we can push, like giving Narcan for an opioid overdose?

Actually, no.

There is no specific antidote to nicotine poisoning.

The treatment is entirely supportive.

You focus on reducing absorption by administering activated charcoal.

And if respiration is depressed, you immediately provide ventilatory assistance.

But here is the critical physiological saving grace.

Because nicotine has that incredibly short half -life of one to two hours, if you can keep the patient's airway supported and manage the symptoms,

recovery from the acute phase of poisoning can actually occur within hours as the kidneys clear the drug.

The juxtaposition is just wild.

A drug that causes decades -long chronic toxicity, like lung cancer, COPD, ischemic heart disease, can also cause fatal acute poisoning within hours.

But let's return to managing that chronic toxicity.

The clinical takeaway from the text is that reversing the damage is entirely possible.

The data from the nurses' health study shows that the risk for COPD or death from a heart attack declines to that of a nonsmoker after 20 years of cessation.

For lung cancer, the risk drops to that of a nonsmoker after 30 years.

The body's ability to heal is remarkable, but getting the patient to that point is the ultimate clinical challenge.

Quitting is incredibly difficult.

Every year, 41 % of Americans who smoke try to quit, but without formal medical help, only 4 % to 7 % achieve long -term success.

But with a combination of counseling and pharmaceutical drugs, that six -month abstinence rate jumps significantly to 25%.

Even then, patients usually try quitting five to seven times before they finally succeed.

The U .S.

Public Health Service guidelines state that tobacco dependence is a chronic condition that warrants repeated intervention until long -term abstinence is achieved.

So clinically, we need to treat tobacco dependence the exact same way we treat a chronic disease, like hypertension or diabetes.

It's not a one -time fix.

It warrants repeated, lifelong management.

Validating that clinical mindset is essential for advanced practice students.

You are treating a chronic, relapsing neurobiological condition, and the clinical guideline provides a clear framework for this, the 5As model.

The 5As.

Ask, advise, assess, assist, arrange.

Exactly.

Ask, so screen all your patients for tobacco use at every visit.

Advise, strongly urge tobacco users to quit.

Assess, determine their willingness to make a quit attempt right now.

Assist, so offer specific medications and provide or refer to counseling.

And arrange, which means schedule follow -up contacts, beginning within the very first week after their quit date.

Let's focus on how we actually assist.

We are moving into rational drug selection, focusing first on nicotine replacement therapy, or NRT.

The textbook provides heavily detailed comparison tables here, specifically table 34 .1 and 34 .3.

The overarching strategy with NRT is fairly straightforward.

You substitute a pharmaceutical source of nicotine for the nicotine in cigarettes,

stabilize the patient, and then gradually withdraw the replacement.

It's conceptually analogous to using methadone to wean a patient from heroin.

You are providing the chemical to relieve the severe physiological withdrawal symptoms, but in a controlled way that produces significantly less subjective pleasure than cigarettes.

Let's break down the actual formulations.

First, nicotine gum and lozenges, which are both nicotine palacrolex.

The dosing parameter here is fascinating.

It's not based on weight, it's based entirely on the patient's morning routine.

Yes, the 30 -minute rule.

Right.

If they have their first cigarette within 30 minutes of waking up, you start them on the higher 4 -milligram dose.

If they wait more than 30 minutes, you start them on the 2 -milligram dose.

That 30 -minute metric is a highly effective clinical proxy for the severity of their physical dependence.

If they need that dopamine hit immediately upon opening their eyes, their overnight withdrawal is severe, requiring the higher 4 -milligram starting dose to manage those morning cravings.

That makes total sense.

But your patient education here is critical.

They absolutely cannot eat or drink for 15 minutes before or during use because the acidity of foods and beverages drastically reduces nicotine absorption in the mouth.

And the administration technique matters immensely too.

For the gum, they can't just chew it rapidly like regular bubble gum.

Rapid chewing releases too much nicotine at once, which hits the stomach and causes severe nausea and hiccup.

Oh yeah, it's very unpleasant.

They have to chew it slowly until it tingles, and then park it between the cheek and gums for about 30 minutes to allow for steady buckle absorption.

The lozenge is similar, just place it in the mouth and let it dissolve slowly over 20 -30 minutes.

No chewing and swallowing.

Next, we have nicotine transdermal systems, or patches.

These provide steady, continuous blood levels over 16 or 24 hours.

They're applied once a day to clean, dry, hairless skin of the upper body, and the application site must be rotated daily to prevent skin irritation.

So what's a dosing schedule like for those?

Looking at table 34 .3, we see a structured step -down approach.

A standard regimen might start at a 21 -milligram patch for several wits, step down to 14 -milligrams, and then finally to 7 -milligrams before stopping.

But you don't start everyone on that large 21 -milligram patch, right?

Patients who weigh less than 100 pounds, patients with active cardiovascular disease, or those who smoke less than half a pack a day need to begin with a smaller patch to avoid nicotine toxicity and undue cardiovascular stress.

Precisely.

You have to tailor the pharmacokinetics to the patient's baseline tolerance.

Now, what about the inhalation methods, the inhaler and the nasal spray?

The nicotine inhaler looks somewhat like a cigarette and mimics that physical hand -to -mouth habit, which is great for patients heavily tied to the behavioral ritual.

But here is the clinical trick.

The nicotine isn't actually absorbed in the lungs, it's deposited and absorbed through the oral mucosa.

Right.

It requires frequent puffing over 20 minutes to get a clinical dose, and it even contains menthol to simulate the harsh throat hit of real smoke.

You do want to avoid prescribing this for patients with asthma, as it can cause bronchospasm.

And finally, the nicotine nasal spray.

This provides the fastest delivery and the highest peak nicotine levels of all the NRTs, most closely simulating the rapid pharmacokinetics of smoking.

Because it's a spray into the nasal cavity.

Exactly.

Because the blood levels rise so rapidly, it actually provides some of the subjective pleasure and immediate relief associated with lighting a cigarette.

Which makes it highly effective for severe cravings.

But the text notes a major downside.

Many patients struggle to wean themselves off the spray itself because of that rapid reward loop.

Plus, it's highly irritating to the nasal mucosa and throat, especially in the first week, and should be strictly avoided in patients with sinus problems, severe allergies, or asthma.

Yes.

So what does this all mean?

Why give a patient the exact chemical they're addicted to, aren't we just trading one addiction for another?

Well, think back to the pharmacokinetics of the 10 -second hijack we discussed earlier.

NRTs entirely eliminate the dangerous tar, carbon monoxide, and carcinogenic gases.

Okay, true.

Furthermore, with the gum, lozenges, patches, and even the inhaler, the blood levels of nicotine rise much more slowly and remain relatively steady.

You are trading the sharp, highly addictive 10 -second dopamine spikes of a cigarette for a slow, steady pharmacokinetic plateau.

Oh, I see.

You are breaking the behavioral reward conditioning, the link between inhaling and immediate pleasure, while physically managing the autonomic withdrawal symptoms.

That makes perfect sense.

You stabilize the physiology so you can actually do the behavioral work.

Now let's move to rational drug selection for non -nicotine products.

Table 34 .4 outlines two specific medications, bupropion SR and verinoclin.

Let's start with bupropion SR, which is classified as an atypical antidepressant.

Its mechanism of action is completely different from NRT.

It works by blocking the neural uptake of norepinephrine and dopamine in the central nervous system.

Right.

By keeping those specific neurotransmitters artificially elevated in the synaptic cleft, it mimics the rewarding effects of nicotine just enough to reduce the physiological urge to smoke and powerfully suppresses withdrawal symptoms like irritability and anxiety.

Now bupropion is structurally very similar to amphetamine.

It stimulates the central nervous system and suppresses appetite.

Is that mechanism why it's so effective at limiting the weight gain typically associated with quitting?

This raises an important question, yes, that is exactly why.

And this highlights a vital concept for advanced practice students, matching patient profiles to drug selection.

Yeah, customizing the care.

Weight gain is a massive psychological barrier for many patients trying to quit.

By actively selecting a drug whose specific side effect profile mitigates that fear, you drastically improve long -term patient compliance.

But there are contraindications, right?

Definitely.

Because its stimulant properties lower the seizure threshold, bupropion is strictly contraindicated in patients with a history of seizures, anorexia nervosa, current cocaine use, or those going through active alcohol withdrawal.

You can't mix it.

Right.

It cannot be mixed with MAO inhibitors or Wellbutrin because Wellbutrin is literally just another trade name for bupropion.

Taking both would lead to an accidental overgoes.

We also have to spend time on the black box warning for bupropion.

Post -marketing reports indicate it can cause serious neuropsychiatric effects, including severe mood changes, erratic behavior, and suicidality.

When you think about it, the brain's chemical balance is already entirely destabilized by the immense stress of nicotine withdrawal.

Introducing a drug that further alters dopamine and norepinephrine pathways can push vulnerable patients over the edge.

You must rigorously educate your patients and their families to monitor for and report any significant changes in behavior or mental status immediately.

Finally, we have varenicline.

Its mechanism of action is highly specialized.

It acts as a partial agonist at alpha -4, beta -2 nicotinic acetylcholine receptors in the brain.

Meaning what, exactly?

This means it binds to the receptors to provide a mild dopamine release, reducing cravings, but it also physically blocks nicotine from binding to those same receptors if the patient slicks up and smokes a cigarette.

Oh, that's clever.

The major adverse effects you need to monitor for are depression, emotional disturbances, and vivid sleep disorders.

Clinically, you also need to watch for significant drug interactions with ethanol and the anti -seizure medication lamotrigine.

So we've tracked the pharmacology of nicotine from its 10 -second absorption in the lungs through its devastating systemic tug -of -war on the organs, all the way to rational, guideline -based drug selection for cessation.

We've seen exactly how a behavioral habit is fundamentally rooted in a hijacked physiological system.

And as we wrap up this clinical review, I want to leave you with a final thought to mull over during your clinical rotations.

We've talked extensively about how nicotine physically rewires the brain's mesolimbic pathways, linking the physical act of smoking to a chemical reward.

But those neural pathways don't just vanish when the nicotine has finally gone from the blood, they lie dormant.

So as a clinician, how might you help a patient redesign their daily physical environment to actively avoid the cues, you know, the morning cup of coffee, the specific driving route to work, the social settings at a bar that can instantly trigger those dormant pathways, even years after their last cigarette?

That's a great point.

Because while pharmacology can successfully stabilize the physical receptors, it is the environment that triggers the memory.

That is exactly the kind of holistic clinical thinking that separates a good practitioner from a truly great one.

You weren't just treating the biology, you were treating the biography.

Thank you so much for joining us for this specialized study section.

From all of us here at the Last Minute Lecture Team, good luck on your clinical rotations, good luck on your exams, and keep diving deep.